Schwab Charles Investment Management Inc. increased its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 10.6% during the first quarter, Holdings Channel reports. The firm owned 626,312 shares of the company’s stock after buying an additional 60,229 shares during the period. Schwab Charles Investment Management Inc.’s holdings in TherapeuticsMD were worth $4,510,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Greenwood Capital Associates LLC boosted its stake in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the period. American International Group Inc. boosted its stake in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares during the period. Stifel Financial Corp boosted its stake in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in TherapeuticsMD during the first quarter valued at $4,176,000.

TherapeuticsMD Inc (NASDAQ TXMD) traded down 0.18% during trading on Friday, hitting $5.66. 2,930,046 shares of the company traded hands. TherapeuticsMD Inc has a 52 week low of $3.50 and a 52 week high of $8.30. The stock’s market capitalization is $1.15 billion. The company’s 50 day moving average is $5.43 and its 200-day moving average is $5.53.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. TherapeuticsMD’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. Analysts predict that TherapeuticsMD Inc will post ($0.41) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Schwab Charles Investment Management Inc. Boosts Position in TherapeuticsMD Inc (TXMD)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/schwab-charles-investment-management-inc-boosts-position-in-therapeuticsmd-inc-txmd.html.

Several research firms have recently weighed in on TXMD. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Friday, August 4th. Jefferies Group LLC restated a “buy” rating and set a $15.00 price objective on shares of TherapeuticsMD in a research report on Friday. Deutsche Bank AG set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating and set a $12.00 target price on shares of TherapeuticsMD in a report on Tuesday, May 9th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and a consensus target price of $16.14.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.